

CITATION REPORT

List of articles citing

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

DOI: 10.1158/1078-0432.ccr-08-0168
Clinical Cancer Research, 2008, 14, 4275-83.

Source: <https://exaly.com/paper-pdf/44514662/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
857	Activating mutations in ALK provide a therapeutic target in neuroblastoma. 2008 , 455, 975-8		652
856	Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. 2008 , 99, 2349-55		180
855	A mouse model for EML4-ALK-positive lung cancer. 2008 , 105, 19893-7		413
854	Inhibition of ALK signaling for cancer therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 5609-14	12.9	125
853	Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. <i>Molecular Cancer Research</i> , 2009 , 7, 1466-76	6.6	242
852	ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. 2009 , 4, 1450-4		244
851	GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. 2009 , 8, 2811-20		84
850	EML4-ALK: honing in on a new target in non-small-cell lung cancer. 2009 , 27, 4232-5		258
849	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. 2009 , 27, 5650-9		103
848	Mutation-associated fusion cancer genes in solid tumors. 2009 , 8, 1399-408		44
847	Highlights From: The 13th World Conference on Lung Cancer San Francisco, CA July 31-August 4, 2009. <i>Clinical Lung Cancer</i> , 2009 , 10, 317-321	4.9	
846	ErbBs in lung cancer. 2009 , 315, 557-71		57
845	Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK). 2009 , 36, S36-41		14
844	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 2009 , 115, 1723-33		598
843	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. 2009 , 22, 508-15		380
842	Transcriptome sequencing to detect gene fusions in cancer. 2009 , 458, 97-101		709
841	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. 2009 , 8, 709-23		259

840	DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure. 2009 , 100, 1336-42		26
839	Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. 2009 , 9, 331-56		168
838	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009 , 27, 4247-53		1462
837	Oncogenic gene fusions in epithelial carcinomas. 2009 , 19, 82-91		60
836	Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. 2009 , 40, 1152-8		157
835	KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3143-9	12.9	590
834	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. 2009 , 174, 661-70		261
833	ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. 2009 , 48, 3600-9		27
832	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. <i>Clinical Cancer Research</i> , 2009 , 15, 5216-23	12.9	560
831	Anaplastic lymphoma kinase: signalling in development and disease. 2009 , 420, 345-61		326
830	Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. 2009 , 4, 787-91		25
829	The genomics of lung adenocarcinoma: opportunities for targeted therapies. 2010 , 1, 1200-10		64
828	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. 2010 , 11, 851-64		40
827	Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. 2010 , 5, 2039-40		64
826	Molecular Diagnostics Testing for Lung Adenocarcinoma. 2010 , 15, 103-110		1
825	Incidentally proven pulmonary "ALKoma". 2010 , 49, 603-6		4
824	EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas. 2010 , 1, 271-275		10
823	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. 2010 , 17, 889-97		266

822	Fusion genes in epithelial neoplasia. 2010 , 63, 4-11		5
821	Impact of biomarkers on non-small cell lung cancer treatment. 2010 , 5, 5-17		14
820	Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. 2010 , 11, 36-44		40
819	Molecular testing in lung cancer: the time is now. 2010 , 12, 335-48		18
818	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. 2010 , 29, 49-60		164
817	The 2010 Meeting of the American Society of Clinical Oncology. <i>Clinical Lung Cancer</i> , 2010 , 11, 303-310	4.9	1
816	Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. 2010 , 80, 613-23		69
815	Somatic mutations of signaling genes in non-small-cell lung cancer. 2010 , 203, 7-15		36
814	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 2010 , 16, 793-8		382
813	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. 2010 , 38, 6985-96		36
812	Targeted therapies for non-small cell lung cancer: an evolving landscape. 2010 , 9, 1931-44		65
811	EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. <i>Clinical Cancer Research</i> , 2010 , 16, 4938-45	12.9	135
810	A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. <i>Clinical Cancer Research</i> , 2010 , 16, 1561-71	12.9	364
809	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. 2010 , 70, 10038-43		264
808	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. <i>Clinical Cancer Research</i> , 2010 , 16, 5581-90	12.9	284
807	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010 , 363, 1693-703		3577
806	Systems Pharmacology in Cancer. 2010 , 377-397		
805	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. 2010 , 70, 9827-36		164

804	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. 2010 , 21, 255-262	156
803	Surgery: Future directions in multimodality therapy for NSCLC. 2010 , 7, 10-2	3
802	Novel agents in the management of lung cancer. 2010 , 17, 4291-325	16
801	Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. 2010 , 4, 499-508	5
800	Targeted Therapies in Lung Cancer. 2010 , 3, 71-82	25
799	Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. 2010 , 49, 6813-25	117
798	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. 2010 , 9, 188	227
797	Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. 2010 , 299, 81-94	44
796	The biology and treatment of EML4-ALK non-small cell lung cancer. 2010 , 46, 1773-80	417
795	The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. 2010 , 46, 2357-68	48
794	It's diagnostics, stupid. 2010 , 141, 13-7	36
793	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. 2010 , 36 Suppl 3, S21-9	97
792	Principles of Clinical Cancer Genetics. 2010 ,	2
791	Common gene rearrangements in prostate cancer. 2011 , 29, 3659-68	231
790	Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. 2011 , 11, 1677-87	23
789	Diagnostic Molecular Pathology in Practice. 2011 ,	1
788	Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. <i>Lung Cancer</i> , 2011 , 72, 309-15	5.9 94
787	EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. <i>Lung Cancer</i> , 2011 , 71, 241-3	5.9 97

786	Lung cancer in never smokers: change of a mindset in the molecular era. <i>Lung Cancer</i> , 2011 , 72, 9-15	5.9	65
785	Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report. <i>Lung Cancer</i> , 2011 , 73, 375-8	5.9	4
784	Role of genotyping in non-small cell lung cancer treatment: current status. 2011 , 71, 2231-46		17
783	9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. 2011 , 54, 6286-94		62
782	Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. 2011 , 365, 158-67		8
781	The potential for crizotinib in non-small cell lung cancer: a perspective review. 2011 , 3, 279-91		62
780	Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. 2011 , 71, 4920-31		174
779	Oncologie thoracique. 2011 , 3, 158-165		
778	Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. <i>Translational Oncology</i> , 2011 , 4, 59-70	4.9	8
777	Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. 2011 , 13, 1-11		51
776	Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. 2011 , 204, 45-52		73
775	New driver mutations in non-small-cell lung cancer. 2011 , 12, 175-80		881
774	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. 2011 , 12, 1004-12		732
773	Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. 2011 , 2, 379-384		27
772	Personalized therapy for non-small cell lung cancer: hype or clinical reality?. 2011 , 23, 30-5		2
771	Lung Cancer Metastasis. 369-381		2
770	EML4 (echinoderm microtubule associated protein like 4). 2011 ,		
769	Lung: non-small cell carcinoma with inv(2)(p21p23). 2011 ,		

768	Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization. 2011 , 6, e17854	3
767	Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer. 2011 , 6, 399-403	3
766	Molecular Biology and Genetics of Lung Cancer. 2011 , 3-15	2
765	What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. 2011 , 43, 103-15	46
764	Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. 2011 , 6, 1962-3	62
763	[Molecular targeted drugs against ALK fusions]. 2011 , 138, 3-7	
762	How I do it--optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples. 2011 , 6, 203-6	92
761	Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. 2011 , 6, 905-12	53
760	A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. 2011 , 6, 1379-91	79
759	Therapeutische Strategien bei SCLC und NSCLC. 2011 , 14, 24-34	
758	Crizotinib and testing for ALK. 2011 , 9, 1335-41	92
757	Oncogenic mutations of ALK in neuroblastoma. 2011 , 102, 302-8	42
756	Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. 2011 , 102, 1602-4	9
755	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. 2011 , 17, 304-12	77
754	Cancer genomics: from discovery science to personalized medicine. 2011 , 17, 297-303	415
753	Advances in the preclinical testing of cancer therapeutic hypotheses. 2011 , 10, 179-87	100
752	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. 2011 , 30, 2581-6	120
751	Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. 2011 , 104, 68-74	73

750	Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. <i>Clinical Lung Cancer</i> , 2011 , 12, 360-8	4.9	22
749	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. 2011 , 5, 413-24		21
748	EGFR mutations and lung cancer. 2011 , 6, 49-69		387
747	Non-small cell lung cancer in never smokers as a representative non-smoking-associated lung cancer epidemiology and clinical features. 2011 , 16, 287-93		78
746	Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). <i>Clinical and Translational Oncology</i> , 2011 , 13, 812-8	3.6	6
745	Mind-mapping for lung cancer: towards a personalized therapeutics approach. 2011 , 28, 173-94		15
744	Targetable "driver" mutations in non small cell lung cancer. 2011 , 2, 178-88		17
743	Clinical cancer genomics: how soon is now?. 2011 , 223, 318-26		30
742	Cancer biology and genomics: translating discoveries, transforming pathology. 2011 , 223, 99-101		4
741	A novel KIF5B-ALK variant in nonsmall cell lung cancer. 2011 , 117, 2709-18		74
740	Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. 2011 , 21, 463-6		31
739	Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. 2011 , 18, 1613-28		30
738	Targeting anaplastic lymphoma kinase in lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2081-6	12.9	230
737	New strategies for treatment of ALK-rearranged non-small cell lung cancers. <i>Clinical Cancer Research</i> , 2011 , 17, 7213-8	12.9	72
736	Lung cancer in never smokers. 2011 , 7, 1195-211		30
735	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. 2011 , 3, 113-25		77
734	Anaplastic lymphoma kinase in human cancer. 2011 , 47, R11-23		96
733	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. 2011 , 71, 6051-60		468

732	Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. 2011 , 10, 806-16		124
731	Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. 2011 , 136, 228-38		33
730	Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2140-8	12.9	109
729	Targeting oncogenic ALK: a promising strategy for cancer treatment. 2011 , 10, 569-79		87
728	Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. 2011 , 16, 164-73		6
727	MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. 2011 , 6, 1624-31		98
726	The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. 2011 , 1, 1119-1126		16
725	Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. 2011 , 71, 5965-75		12
724	ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. <i>Clinical Cancer Research</i> , 2011 , 17, 7394-401	12.9	147
723	Genetic testing for lung cancer: reflex versus clinical selection. 2011 , 29, 1943-5		13
722	Characterization of KRAS rearrangements in metastatic prostate cancer. 2011 , 1, 35-43		83
721	Advancing personalized cancer medicine in lung cancer. 2012 , 136, 1210-6		6
720	Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. <i>Clinical Cancer Research</i> , 2012 , 18, 4682-90	12.9	191
719	Molecular diagnostics of lung cancers at the Brigham and Women [®] Hospital and Dana-Farber Cancer Institute: technology in rapid evolution. 2012 , 136, 1198-200		7
718	Anaplastic lymphoma kinase () inhibitors for second-line therapy of non-small cell lung cancer. 2012 , 3, 91-99		2
717	The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. 2012 , 19, S24-32		25
716	Rare cancer trial design: lessons from FDA approvals. <i>Clinical Cancer Research</i> , 2012 , 18, 5172-8	12.9	38
715	Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. 2012 , 7, 1315-26		135

714	Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. 2012 , 23, 2931-2936		32
713	Microtubule-Associated Protein-Like 4 Anaplastic Lymphoma Kinase Rearrangement in Lung Adenocarcinoma. 2012 , 17, 202-206		
712	RNA-Seq mapping and detection of gene fusions with a suffix array algorithm. 2012 , 8, e1002464		40
711	Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. 2012 , 30, e147-50		43
710	Cancer genes in lung cancer: racial disparities: are there any?. 2012 , 3, 467-80		92
709	Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. 2012 , 19, 3689-700		10
708	Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. <i>Clinical Cancer Research</i> , 2012 , 18, 3592-602	12.9	93
707	The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. 2012 , 1, 259-272		20
706	A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 5682-9	12.9	109
705	Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. 2012 , 106, 763-7		38
704	New developments in the treatment of ALK-driven malignancies. 2012 , 2, 835-852		1
703	Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 6219-26	12.9	123
702	Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?. 2012 , 13, 1376-83		81
701	CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. 2012 , 11, 670-9		60
700	The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. 2012 , 16 Suppl 2, S45-54		16
699	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 2012 , 4, 120ra17		948
698	ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. <i>Frontiers in Oncology</i> , 2012 , 2, 41	5.3	33
697	Genetic and biochemical alterations in non-small cell lung cancer. 2012 , 2012, 940405		34

696	ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. 2012 , 23, 2907-2913	122
695	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. 2012 , 7, 348-54	170
694	Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. 2012 , 142, 1020-1026	43
693	Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements. 2012 , 2, 895-907	1
692	Non-small cell lung cancer. 2012 , 10, 1236-71	270
691	A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. 2012 , 28, 1225-30	4
690	A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer. 2012 , 7, 913-8	14
689	Gene fusions in non-small-cell lung cancer. 2012 , 1, 283-292	1
688	Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. 2012 , 7, 1872-1876	71
687	Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. 2012 , 7, e1-2	48
686	Targeting ALK, ROS1, and BRAF kinases. 2012 , 7, S375-6	10
685	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. 2012 , 7, 98-104	76
684	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. 2012 , 17, 1351-75	175
683	Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. <i>Clinical Cancer Research</i> , 2012 , 18, 3737-42	12.9 64
682	Advances in treatment of lung cancer with targeted therapy. 2012 , 136, 504-9	57
681	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. <i>Lung Cancer</i> , 2012 , 77, 319-25	5.9 89
680	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2012 , 77, 288-92	5.9 102
679	Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. 2012 , 23, 1738-43	42

678	Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. 2012 , 136, 796-803	98
677	Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts. 2012 , 131, 1453-1466	21
676	Molecular markers for incidence, prognosis, and response to therapy. 2012 , 21, 161-75	6
675	Targeted therapy of non-small-cell lung carcinoma. 2012 , 6, 41-56	3
674	Translating genomic information into clinical medicine: lung cancer as a paradigm. 2012 , 22, 2101-8	64
673	Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1.1]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles. 2012 , 55, 449-64	33
672	Targeted therapy for NSCLC: ALK inhibition. 2012 , 18, 271-4	6
671	Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. 2012 , 22, 928-31	63
670	ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. 2012 , 48, 961-73	71
669	Lung cancer in never smokers--a review. 2012 , 48, 1299-311	280
668	Crizotinib in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1195-201	4 60
667	The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein. 2012 , 12, 229	11
666	A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. 2012 , 12, 558	33
665	EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. 2012 , 83, 248-56	36
664	Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. 2012 , 12, 277-86	29
663	ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. <i>Lung Cancer</i> , 2012 , 75, 66-72	5.9 25
662	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. <i>Lung Cancer</i> , 2012 , 76, 403-9	5.9 130
661	Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. <i>Lung Cancer</i> , 2012 , 77, 293-8	5.9 20

660	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , 2012 , 77, 460-3	5.9	71
659	Treating ALK-positive lung cancer--early successes and future challenges. 2012 , 9, 268-77		195
658	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin \odot lymphoma, and neuroblastoma. 2012 , 7, 199-210		25
657	Molecular Diagnosis of Lung Cancer. 2012 , 87-97		
656	Molecular Pathology of Lung Cancer. 2012 ,		5
655	Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. 2012 , 12, 612		34
654	Tyrosine kinase inhibitors in lung cancer. 2012 , 26, 589-605, viii		24
653	Next-generation cDNA screening for oncogene and resistance phenotypes. 2012 , 7, e49201		8
652	EML4-ALK fusion gene in Korean non-small cell lung cancer. 2012 , 27, 228-30		16
651	ALK Inhibitors, a Pharmaceutical Perspective. <i>Frontiers in Oncology</i> , 2012 , 2, 17	5.3	17
650	A Screening Method for the ALK Fusion Gene in NSCLC. <i>Frontiers in Oncology</i> , 2012 , 2, 24	5.3	59
649	Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. 2012 , 67, 845-7		15
648	ALKoma: a cancer subtype with a shared target. 2012 , 2, 495-502		141
647	Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 925-32	5	20
646	A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. 2012 , 131, 970-9		7
645	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. 2012 , 118, 3579-86		41
644	Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. 2012 , 118, 5302-9		68
643	Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors. 2012 , 55, 115-25		25

642	Histologic and cytomorphic features of ALK-rearranged lung adenocarcinomas. 2012 , 25, 1462-72		83
641	Driver mutations as predictive biomarkers in lung cancer. 2012 , 1, 21-29		
640	The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. 2012 , 14, 105-10		32
639	ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment. 2012 , 190, 381-8		7
638	Pulmonary adenocarcinoma: a renewed entity in 2011. 2012 , 17, 50-65		56
637	Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. 2012 , 60, 187-98		49
636	Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). 2012 , 20, 1271-80		131
635	Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 54-65	5	21
634	Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 590-7	5	67
633	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. 2012 , 118, 729-39		114
632	Cancer Genomics. 2013 ,		4
631	The impact of genomic changes on treatment of lung cancer. 2013 , 188, 770-5		76
630	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs. 2013 , 1, 67-76		
629	Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. 2013 , 13, 262		39
628	Fool@ gold, lost treasures, and the randomized clinical trial. 2013 , 13, 193		36
627	Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. 2013 , 13, 8		4
626	Diagnostic Pathology of Pleuropulmonary Neoplasia. 2013 ,		3
625	Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. 2013 , 36, 1051-4		16

624	Array Comparative Genomic Hybridization. 2013,		1
623	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. 2013, 8, 55-67		66
622	60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. 2013,		7
621	Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. 2013, 119, 1467-77		59
620	Biologic approaches to drug selection and targeted therapy: hype or clinical reality?. 2013, 23, 421-8		3
619	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. 2013, 26, 1545-53		119
618	Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. 2013, 23, 6192-6		18
617	Crizotinib in the treatment of non--small-cell lung cancer. <i>Clinical Lung Cancer, 2013, 14, 473-80</i>	4.9	32
616	Genetic alterations defining NSCLC subtypes and their therapeutic implications. <i>Lung Cancer, 2013, 82, 179-89</i>	5.9	189
615	Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. 2013, 1, 251-61		57
614	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. <i>Lung Cancer, 2013, 81, 377-381</i>	5.9	7
613	ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer. 2013, 24, 356-64		39
612	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. <i>Clinical Cancer Research, 2013, 19, 4273-81</i>	12.9	411
611	Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. 2013, 2, 409		19
610	Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. 2013, 13, 466		26
609	Pharmacogenomics in Drug Discovery and Development. 2013, 353-361		
608	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. 2013, 13, 407-20		14
607	Molecular Pathology of Lung Cancer. 2013, 443-459		

606	Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2013 , 79, 40-5	5.9	27
605	KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. 2013 , 119, 1486-94		44
604	Clinical testing for molecular targets for personalized treatment in lung cancer. 2013 , 18, 233-7		3
603	The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. 2013 , 96, 1196-1202		68
602	ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. 2013 , 206, 357-73		43
601	Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. 2013 , 31, 3987-96		260
600	Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. <i>Lung Cancer</i> , 2013 , 79, 242-7	5.9	51
599	Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. <i>Lung Cancer</i> , 2013 , 81, 294-6	5.9	30
598	[Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer]. 2013 , 69, 111-6		
597	Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. 2013 , 102, 157-62		40
596	Applications of array-CGH for lung cancer. 2013 , 973, 297-324		4
595	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , 2013 , 19, 279-90	12.9	649
594	Jelly Belly trans-synaptic signaling to anaplastic lymphoma kinase regulates neurotransmission strength and synapse architecture. 2013 , 73, 189-208		16
593	Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. 2013 , 20, 211-21		49
592	Molecular biology of lung cancer-a review. 2013 , 4, 120-4		14
591	Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. <i>Lung Cancer</i> , 2013 , 81, 200-6	5.9	42
590	Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. 2013 , 18, 11-24		7
589	Companion diagnostic testing for targeted cancer therapies: an overview. 2013 , 17, 515-23		13

588	Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. 2013 , 6, 25-36		21
587	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 15, 415-53		340
586	Characterization of gene rearrangements resulted from genomic structural aberrations in human esophageal squamous cell carcinoma KYSE150 cells. 2013 , 513, 196-201		13
585	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 137, 828-60		365
584	Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?. 2013 , 10, 636-43		76
583	PROFILING non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 597-608	4	6
582	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 8, 823-59		632
581	Advances in personalized therapy for lung cancer. 2013 , 7, 475-85		8
580	Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. 2013 , 26, 1468-77		28
579	[Crizotinib - molecular therapy for lung cancer]. 2013 , 67, 205-8		3
578	Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. 2013 , 2013, 757490		41
577	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. 2013 , 1, 575-581		37
576	Targeted inhibition in tumors with ALK dependency. 2013 , 4, 1-8		1
575	A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. 2013 , 50, 80-6		25
574	Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer?. 2013 , 31, 2236-9		13
573	Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. 2013 , 19, 238-46		9
572	Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. 2013 , 3, 630-5		383
571	Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer. 2013 , 19, 263-71		4

570	A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. 2013 , 73, 5508-18	173
569	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. 2013 , 5, 249-70	34
568	ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. 2013 , 12, 696-704	42
567	Tissue acquisition and specimen processing in the diagnosis of NSCLC. 2013 , 34, 787-91	3
566	Emerging options for the management of non-small cell lung cancer. 2013 , 7, 221-34	14
565	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. 2013 , 39, 328-35	48
564	Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. 2013 , 26, 646-53	35
563	High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. 2013 , 121, 311-9	44
562	Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. 2013 , 8, 883-91	56
561	CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. 2013 , 8, 1378-88	51
560	Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. 2013 , 8, 352-8	40
559	MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. 2013 , 8, 574-81	42
558	Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor. 2013 , 11, 1466-70	17
557	Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. 2013 , 8, 45-51	225
556	EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. 2013 , 6, 316-9	7
555	[Pharmacology profile of crizotinib (Xalkori(®))Capsules) and clinical findings on this drug]. 2013 , 141, 106-13	1
554	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. 2013 , 8, e52093	82
553	Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. 2013 , 8, e52261	58

552	A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. 2013 , 8, e69794	33
551	Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. 2013 , 8, e70839	79
550	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. 2013 , 8, e82236	85
549	Lung cancer. 506-525	
548	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. 2013 , e272-e278	4
547	Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. 2014 , 9, e99409	139
546	The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. 2014 , 9, e84501	19
545	Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. 2014 , 9, e114008	17
544	Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation. 2014 , 19, 3508-22	36
543	Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. 2014 , 5, 1048-54	45
542	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. 2014 , 7, 375-85	20
541	Management and future directions in non-small cell lung cancer with known activating mutations. 2014 , e353-65	62
540	Patterns of ALK expression in different human cancer types. 2014 , 67, 477-81	5
539	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. 2014 , 14, 834	12
538	Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. 2014 , 15, 570-7	58
537	Evaluating the utility of local therapy for oligometastatic lung cancer. 2014 , 3, 373-381	
536	RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. 2014 , 110, 1571-8	97
535	Oncogenic RIT1 mutations in lung adenocarcinoma. 2014 , 33, 4418-23	56

534	Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer. 2014 , 5, 255-60		3
533	Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. 2014 , 5, 1-9		27
532	Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR-145 through the ERK1/2 in non-small cell lung cancer. 2014 , 31, 1940-6		18
531	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. 2014 , 10, 1081-93		5
530	Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. 2014 , 74, 7217-7228		39
529	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. 2014 , 5, 5893		100
528	ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 895-901	5	13
527	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. <i>Clinical Cancer Research</i> , 2014 , 20, 1383-92	12.9	121
526	Molecular alterations in non-small cell lung carcinomas of the young. 2014 , 45, 2379-87		32
525	A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. 2014 , 799, 85-117		76
524	Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. 2014 , 65, 398-407		49
523	Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. 2014 , 110, 245-51		27
522	The evolving genomic classification of lung cancer. 2014 , 232, 121-33		74
521	Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma. 2014 , 122, 810-21		26
520	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. <i>Molecular Cancer Research</i> , 2014 , 12, 111-8	6.6	90
519	Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. 2014 , 9, 1171-9		57
518	Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. 2014 , 9, 307-15		23
517	Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. 2014 , 9, 248-53		11

516	HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. 2014 , 9, 285-94		68
515	Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. 2014 , 9, 295-306		130
514	Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. 2014 , 9, 18-25		55
513	Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. 2014 , 9, 1685-92		52
512	A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. 2014 , 9, 1638-46		12
511	A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. 2014 , 44, 963-8		10
510	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. 2014 , 14, 1495-513		6
509	Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. 2014 , 6, 423-32		90
508	Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective. <i>Frontiers in Oncology</i> , 2014 , 4, 182	5:3	14
507	Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group. 2014 , 48, 1-9		18
506	A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. 2014 , 9, 769-74		37
505	Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. 2014 , 38, 1118-27		104
504	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. 2014 , 134, 1484-94		106
503	Detection of gene rearrangements in targeted clinical next-generation sequencing. 2014 , 16, 405-17		59
502	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014 , 83, 259-64	5:9	26
501	Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing. <i>Lung Cancer</i> , 2014 , 84, 215-21	5:9	25
500	Extending survival of stage IV non-small cell lung cancer. 2014 , 41, 69-92		32
499	ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. 2014 , 37, 1130-8		9

498	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. 2014 , 20, 548-54		1363
497	[Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology]. 2014 , 35, 93-105		
496	Ceritinib in ALK-rearranged non-small-cell lung cancer. 2014 , 370, 1189-97		1119
495	Systems analysis of human multigene disorders. Preface. 2014 , 799, v - viii		3
494	3D-QSAR and molecular fragment replacement study on diaminopyrimidine and pyrrolotriazine ALK inhibitors. 2014 , 1067, 127-137		9
493	ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. 2014 , 120, 2392-402		46
492	Protein kinase inhibitors to treat non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1203-13	4	16
491	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. 2014 , 4, 662-673		591
490	Section IV: non-small cell lung cancer and malignant melanoma. 2014 , 38, 180-98		2
489	Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. <i>Cancer Medicine</i> , 2014 , 3, 118-23	4.8	16
488	Aspects biologiques des cancers bronchiques. 2014 , 6, 311-319		
487	Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies. 2014 , 406, 7389-96		15
486	Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents. 2014 , 115, 611-24		1
485	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. 2014 , 122, 445-53		38
484	Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. <i>Lung Cancer</i> , 2014 , 86, 291-5	5.9	51
483	Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. 2014 , 96, 182-91		17
482	Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer. 2014 , 35, 9759-67		13
481	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. <i>Clinical Cancer Research</i> , 2014 , 20, 5686-96	12.9	227

480	U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. <i>Clinical Cancer Research</i> , 2014 , 20, 2029-34	12.9	101
479	Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. 2014 , 5, 4577		88
478	Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. 2014 , 74, 437-46		21
477	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. 2014 , 23, 1527-37		13
476	Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. <i>Translational Oncology</i> , 2014 , 7, 363-74.9		20
475	Current concepts on the molecular pathology of non-small cell lung carcinoma. 2014 , 31, 306-13		31
474	State of the art: Response assessment in lung cancer in the era of genomic medicine. 2014 , 271, 6-27		92
473	Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. 2014 , 108, 388-94		33
472	Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients. 2014 , 45, 1414-22		10
471	Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. <i>Lung Cancer</i> , 2014 , 84, 110-5	5.9	36
470	Review of the current targeted therapies for non-small-cell lung cancer. 2014 , 5, 576-87		50
469	ALK testing for the right patients: integration into practice and impact on clinics. 2014 , 3, 53-65		
468	Targeting ALK Rearrangements. 2014 , 541-556		1
467	Proteome research in urothelial carcinoma. 2015 , 22, 621-8		4
466	A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review. 2015 , 12, 4370-4375		12
465	A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. 2014 , 4, 7268		24
464	A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement. 2015 , 54, 2741-3		3
463	translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. 2015 , 10, 3385-3392		5

462	Pathological complete response of a patient with ALK-translocated adenocarcinoma of the lung upon treatment with crizotinib followed by alectinib. 2015 , 4, 131-133	2
461	Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. 2015 , 34, 404-12	10
460	Design, Synthesis, and Evaluation of 2-Anilino-4-(3,5-dicarboxamidospiperidine)-pyrimidines as Anaplastic Lymphoma Kinase Inhibitors. 2015 , 36, 2397-2400	
459	The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer. 2015 , 23, 239-44	15
458	Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer. 2015 , 65, 231-9	1
457	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. 2015 , 10, 55-68	22
456	Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. 2015 , 30, e254-7	12
455	From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. 2015 , 21, 413-24	2
454	Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique. 2015 , 23, 245-54	12
453	ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. 2015 , 43, 941-6	36
452	A Case Report of a Metastatic Adenocarcinoma of Lung with Dual Positivity for EGFR Mutation and ALK Fusion. 2015 , 06,	
451	The Pharmaceutical Applications of Next Generation Sequencing in Oncology Drug Designing and Development. 2015 , 02,	0
450	Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. 2015 , 8, 999-1007	10
449	Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. 2015 , e165-73	13
448	Molecular testing and personalized treatment of lung cancer. 2014 , 7, 22-32	17
447	Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. 2015 , 8, 885-92	10
446	Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods. 2015 , 10, e0117032	33
445	Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. 2015 , 10, e0120852	58

444	Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. 2015 , 10, e0120422		71
443	New strategies to develop new medications for lung cancer and metastasis. 2015 , 34, 265-75		10
442	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4014-21	12.9	308
441	Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines. 2015 , 8, 195-209		3
440	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. 2015 , 12, 1978-85		117
439	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015 , 87, 211-9	5.9	44
438	In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. 2015 , 106, 244-52		30
437	Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase. 2015 , 25, 1047-52		10
436	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. 2015 , 33, 1881-8		454
435	Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. 2015 , 18, 312-22		56
434	Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. 2015 , 26, 348-54		109
433	Molecular histology of lung cancer: from targets to treatments. 2015 , 41, 361-75		117
432	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. <i>Clinical Lung Cancer</i> , 2015 , 16, e83-9	4.9	31
431	A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. 2015 , 26, 354-62		98
430	ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. 2015 , 39, 307-12		16
429	Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 2015 , 8, 461-77		26
428	Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. 2015 , 114, 173-81		29
427	Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. 2015 , 20, 316-22		125

426	Ultrafast quantitative MS-based method for ceritinib analysis in human plasma samples from clinical trial. 2015 , 7, 425-35		5
425	Response to erlotinib in a patient with lung adenocarcinoma harbouring the translocation: A case report. 2015 , 9, 1537-1540		6
424	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. 2015 , 45, 55-66		23
423	Understanding next generation sequencing in oncology: A guide for oncologists. 2015 , 96, 463-74		28
422	Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. 2015 , 25, 3992-8		11
421	Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. 2015 , 1, 8		11
420	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. 2015 , 9, 255-68		21
419	French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. 2015 , 46, 207-18		47
418	The ALK Receptor Family. 2015 , 1-51		
417	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. <i>Lung Cancer</i> , 2015 , 90, 255-60	5.9	34
416	Lung cancer: Biology and treatment options. 2015 , 1856, 189-210		322
415	Lung and Mediastinal Tumors. 2015 , 221-268		
414	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. 2015 , 7, 274-90		18
413	ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. <i>Lung Cancer</i> , 2015 , 90, 465-71	5.9	33
412	Metabolism, excretion and pharmacokinetics of [¹⁴ C]crizotinib following oral administration to healthy subjects. 2015 , 45, 45-59		38
411	Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient. 2015 , 23, 111-5		9
410	Genomic Applications in Pathology. 2015 ,		
409	Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. 2016 , 23, 196-200		12

408	Targeted therapies and immunotherapy in non-small-cell lung cancer. 2016 , 10, 648		20
407	Epidemiology of Lung Cancer in Korea: Recent Trends. 2016 , 79, 58-69		89
406	Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients. 2016 , 9, 4671-9		1
405	Crizotinib Induced Rapid Remissions of Lung Adenocarcinoma. 2016 , 02,		
404	Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. 2016 , 5, 579-587		5
403	ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. <i>Oncotarget</i> , 2016 , 7, 12289-304	3-3	21
402	Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. 2016 , 9, 1989-95		15
401	Non-small cell lung cancer: current treatment and future advances. 2016 , 5, 288-300		762
400	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. <i>Frontiers in Oncology</i> , 2016 , 6, 112	5-3	20
399	cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. 2016 , 126, 2267-79		139
398	Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. 2016 , 158, 219-32		27
397	Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1693-701	4	5
396	La cancérogenèse. 2016 , 8, 319-324		
395	Assessment of gene fusions in lung cancer using the differential expression and exon integrity methods. 2016 , 11, 1651-1656		1
394	Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. 2016 ,		2
393	Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib. <i>Clinical Lung Cancer</i> , 2016 , 17, 528-534	4-9	30
392	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers. 2016 , 76, 243-8		2
391	Initial Diagnosis of ALK-Positive Non-Small-Cell Lung Cancer Based on Analysis of ALK Status Utilizing Droplet Digital PCR. 2016 , 88, 4879-85		10

390	A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer. 2016 , 35, 6132-6142		26
389	Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs. 2016 , 22, 231		10
388	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2253-2266	4	22
387	The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. 2016 , 12, 2713-2727		16
386	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. 2016 , 388, 1002-11		113
385	Diagnosis and Molecular Classification of Lung Cancer. 2016 , 170, 25-46		84
384	Molecular Evolution Patterns in Metastatic Lymph Nodes Reflect the Differential Treatment Response of Advanced Primary Lung Cancer. 2016 , 76, 6568-6576		11
383	NonSmall Cell Lung Cancer. 2016 , 809-842.e8		
382	Lung cancer incidence in never smokers: Genetic and gender basis. 2016 , 4, 198-207		6
381	Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. 2016 , 59, 12-19		15
380	Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. 2016 , 9, rs12		19
379	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. <i>Lung Cancer</i> , 2016 , 102, 122-134	5.9	98
378	Resistance to Tyrosine Kinase Inhibitors. 2016 ,		1
377	Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. <i>Cancer Control</i> , 2016 , 23, 338-346	2.2	47
376	SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. 2016 , 39, 681-686		3
375	ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis. 2016 , 31, e413-e421		11
374	Discovering and understanding oncogenic gene fusions through data intensive computational approaches. 2016 , 44, 4487-503		88
373	Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. 2016 , 11, 1550-7		29

372	Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. <i>Lung Cancer</i> , 2016 , 98, 9-14	5.9	24
371	Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, 474-482	4.9	14
370	First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. 2016 , 9, 23		19
369	Inflammatory myofibroblastic tumour-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma. 2016 , 69, 510-5		
368	On the pharmacogenetics of non-small cell lung cancer treatment. 2016 , 12, 307-17		20
367	An integrated molecular modeling approach for in silico design of new tetracyclic derivatives as ALK inhibitors. 2016 , 36, 488-504		9
366	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. 2016 , 9, 203-14		5
365	Protein Kinase C β Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. 2016 , 29, 367-378		61
364	ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. <i>Lung Cancer</i> , 2016 , 94, 22-7	5.9	43
363	Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients. 2016 , 12, 1243-9		4
362	Immune checkpoint therapy for non-small-cell lung cancer: an update. 2016 , 8, 279-98		50
361	Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer. 2016 , 12, 945-61		14
360	Haplotyping germline and cancer genomes with high-throughput linked-read sequencing. 2016 , 34, 303-11		432
359	Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies. 2016 , 26, 1720-5		4
358	High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. 2016 , 34, 419-23		127
357	Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. 2016 , 73, 1209-24		62
356	Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations. 2016 , 101, 473-80		40
355	Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. 2016 , 142, 833-43		12

354	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. 2016 , 16, 147-57		27
353	ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. 2016 , 8, 32-47		83
352	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. 2016 , 890, 1-23		5
351	EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. <i>Clinical Lung Cancer</i> , 2016 , 17, 56-61	4.9	22
350	Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer. 2017 , 40, 631-638		17
349	Genetic inhibition of Anaplastic Lymphoma Kinase rescues cognitive impairments in Neurofibromatosis 1 mutant mice. 2017 , 321, 148-156		12
348	Optimal management of ALK-positive NSCLC progressing on crizotinib. <i>Lung Cancer</i> , 2017 , 106, 58-66	5.9	24
347	Assessment of gene rearrangement in lung cancer using a new rapid automated SureFISH (Dako Omnis) assay. 2017 , 70, 712-714		3
346	Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. 2017 , 177, 1-8		21
345	A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. 2017 , 12, 804-813		32
344	Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. 2017 , 34, 1145-1156		13
343	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. 2017 , 77, 3551-3563		44
342	Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. 2017 , 27, 2185-2191		8
341	AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling. 2017 , 7, 472-476		8
340	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. 2017 , 26, 713-722		11
339	Discovery of a potent dual ALK and EGFR T790M inhibitor. 2017 , 136, 497-510		19
338	Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors. 2017 , 118, 3462-3471		17
337	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. 2017 , 60, 9205-9221		13

336	Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. 2017 , 7, 12510		59
335	Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. 2017 , 28, 1141-1149		16
334	A Rare Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib. 2017 , 1, 111-116		19
333	Pharmacological inhibition of Anaplastic Lymphoma Kinase rescues spatial memory impairments in Neurofibromatosis 1 mutant mice. 2017 , 332, 337-342		8
332	Concurrent driver mutations/rearrangements in non-small-cell lung cancer. 2017 , 29, 118-122		7
331	Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. 2017 , 19, 682-696		42
330	Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant mutation and gene rearrangement: A case report and review of the literature. 2017 , 7, 173-182		2
329	Omics technologies in diagnosis of lung adenocarcinoma. 2017 , 11, 309-340		
328	Pathology and Molecular Pathology of Lung Cancer. 2017 , 367-390		1
327	[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement]. 2017 , 34, 576-580		4
326	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. 2017 , 34, 8-19		15
325	ALK alterations and inhibition in lung cancer. 2017 , 42, 81-88		20
324	EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. <i>Cancers</i> , 2017 , 9,	6.6	84
323	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. 2017 , 11, 2047-2063		19
322	Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. 2017 , 51, 1533-1540		12
321	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. <i>Cancers</i> , 2017 , 9,	6.6	15
320	HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC. 2017 , 51, 599-606		3
319	Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. 2017 , 8, 169-177		8

318	Recent advances in the management of non-small cell lung cancer. 2017 , 6, 2110		16
317	Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with rearrangement. <i>Oncotarget</i> , 2017 , 8, 86066-86081	3.3	11
316	A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay. 2017 , 9, 2311-2314		
315	An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients. 2018 , 153, 1-8		6
314	The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. 2018 , 14, 1897-1908		5
313	Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. 2018 , 8, 3482		14
312	Clinicopathological features of younger (aged ≥ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene. 2018 , 9, 563-570		8
311	ALK-rearrangement in non-small-cell lung cancer (NSCLC). 2018 , 9, 423-430		88
310	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. 2018 , 35, 72		19
309	Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 119, 103-111	5.9	15
308	Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. 2018 , 28, 693-695		116
307	Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer. 2018 , 11, 196-204		1
306	Targeted cancer therapies: Oral health care implications. 2018 , 149, 100-111		7
305	Role of artificial intelligence in the care of patients with nonsmall cell lung cancer. 2018 , 48, e12901		38
304	Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology. 2018 , 36, 37-58		12
303	Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 1691-1704	12.9	33
302	Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer. 2018 , 13, 715-720		31
301	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018 , 24, 2771-2779	12.9	86

300	Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer. 2018 , 28, 77-86		5
299	In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. 2018 , 48, 546-554		13
298	Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. <i>Clinical and Translational Oncology</i> , 2018 , 20, 140-149	3.6	3
297	ALK Inhibitor Response in Melanomas Expressing Fusions and Alternate Isoforms. 2018 , 17, 222-231		24
296	Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration. 2018 , 37, 502-511		21
295	Copy Number Abnormalities and Gene Fusions in Lung Cancer: Present and Developing Technologies. 2018 , 82-94.e4		
294	Clinical Presentation and Prognostic Factors in Lung Cancer. 2018 , 186-198.e6		
293	Molecular Testing in Lung Cancer. 2018 , 164-177.e5		
292	GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors. <i>Lung Cancer</i> , 2018 , 115, 5-11	5.9	15
291	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. 2018 , 4, 1-9		2
290	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. 2018 , 36, 1199-1206		155
289	Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. <i>Oncotarget</i> , 2018 , 9, 4102-4108	3.3	27
288	Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. 2018 , 10, 2070-2078		8
287	Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma. 2018 , 10, 3460-3467		15
286	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. 2018 , 10, 2948-2959		2
285	Management of Advanced NonSmall Cell Lung Cancer. 2018 , 99-115		1
284	Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives. 2019 , 17, 2020-2030		20
283	Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR. 2018 , 18, 1136		8

282	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. 2018 , 19, 1654-1667	361
281	Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non-small-cell lung cancer. 2018 , 18, 1277	1
280	ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. 2018 , 11, 147-155	10
279	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. 2018 , 379, 2027-2039	427
278	ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria. 2018 , 60, 397-401	
277	Relationship of Radiometabolic Biomarkers to KRAS Mutation Status and ALK Rearrangements in Cases of Lung Adenocarcinoma. 2017 , tj5000695	
276	Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. 2018 , 19, 37	7
275	Standardizing biomarker testing for Canadian patients with advanced lung cancer. 2018 , 25, 73-82	16
274	Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. 2018 , 7,	6
273	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. 2018 , 35, 177	35
272	Identification and biological evaluation of glycol diaryl ethers as novel anti-cancer agents through structure-based optimization of crizotinib. 2018 , 92, 1972-1980	
271	Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.. 2018 , 8, 16470-16493	4
270	Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy. 2018 , 7, 79-91	5
269	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018 , 124, 168-178	5.9 15
268	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. 2018 , 15, 694-708	151
267	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. 2018 , 18, 828	15
266	Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization. 2018 , 142, 922-928	14
265	A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206. 2018 , 13, e0193344	12

264	Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. 2018 , 9, 1005-1011	1
263	Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. 2018 , 57, 2377-2382	5
262	Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro. 2019 , 234, 1560-1566	17
261	Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). 2019 , 62, 10927-10954	44
260	The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma. 2019 , 5, 65-69	2
259	The role of amplification and overexpression in therapeutic resistance of malignant tumors. 2019 , 19, 216	61
258	The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis. <i>Cancers</i> , 2019 , 11, 6.6	29
257	The prevalence of variants in patients with non-small-cell lung cancer: a systematic review and meta-analysis. 2019 , 13, 1035-1044	5
256	Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer. 2019 , 42, 599-606	9
255	Chinese perspectives on clinical efficacy and safety of alectinib in patients with -positive advanced non-small cell lung cancer. 2019 , 12, 6481-6495	3
254	Discovery of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines as potent anaplastic lymphoma kinase (ALK) inhibitors. 2019 , 29, 912-916	9
253	Targeting the KRAS, p38 β and NF- κ B in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor. 2019 , 120, 10670-10677	11
252	Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. 2019 , 178, 141-153	4
251	Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. 2019 , 10, 954	43
250	Targeted Therapies for Lung Cancer. 2019 ,	
249	Transbronchial cryobiopsy in diffuse parenchymal lung disease. 2019 ,	
248	Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens. 2019 , 110, 2044-2049	8
247	Clinical Management of Adverse Events Associated with Lorlatinib. 2019 , 24, 1103-1110	44

246	The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors. 2019 , 22, 414-420		7
245	The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 129	5.3	42
244	Targeting chromatin complexes in fusion protein-driven malignancies. 2019 , 19, 255-269		32
243	The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2019 , 132, 79-86	5.9	12
242	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. 2019 , 511, 260-265		10
241	Anaplastic lymphoma kinase expression in small-cell lung cancer. 2019 , 75, 20-28		3
240	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of Mutation Status. 2019 , 79, 1658-1670		44
239	Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland. 2019 , 14, 18		7
238	Lung cancer family history and exposure to occupational/domestic coal combustion contribute to variations in clinicopathologic features and gene fusion patterns in non-small cell lung cancer. 2019 , 10, 695-707		4
237	Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer. 2019 , 112, 108590		0
236	Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma. 2019 , 105, 501-508		
235	Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. 2019 , 30, e0787		7
234	Radiographic Features of Metastatic Brain Tumors from ALK-rearranged Non-small Cell Lung Cancer: Implications for Optimal Treatment Modalities. 2019 , 10, 6660-6665		3
233	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. 2019 , 8,		4
232	Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. 2019 , 9, 18842		9
231	Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. 2019 , 19, 1061-1075		3
230	Fluorometric Detection of Oncogenic EML4-ALK Fusion Gene based on a Graphene Oxide System. 2019 , 13, 370-377		3
229	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. <i>Molecular Cancer Research</i> , 2019 , 17, 212-224	6.6	25

228	Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America. 2019 , 96, 207-216		15
227	Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer. 2019 , 111, 664-674		8
226	New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment. 2019 , 295, 250-267		69
225	Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis. 2019 , 14, e0208646		4
224	A review of existing and new methods of bronchoscopic diagnosis of lung cancer. 2019 , 57, 3-8		11
223	Rapid detection and genotyping of ALK fusion variants by adapter multiplex PCR and high-resolution melting analysis. 2020 , 100, 110-119		
222	Cancer of the Lung: NonSmall Cell Lung Cancer and Small Cell Lung Cancer. 2020 , 1108-1158.e16		5
221	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 242-255	12.9	55
220	Penfluridol: An antipsychotic agent suppresses lung cancer cell growth and metastasis by inducing G0/G1 arrest and apoptosis. 2020 , 121, 109598		7
219	From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. 2019 , 121, 3986		3
218	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. 2020 , 15, 404-415		53
217	Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. 2020 , 111, 3726-3738		3
216	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. 2020 , 9, 2214-2232		17
215	Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the Transcript in H3122 Lung Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
214	Later-Line Treatment with Lorlatinib in - and -Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. 2020 , 13,		5
213	Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. 2020 , 22, 84		7
212	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. 2020 , 38, 3592-3603		104
211	Catalog of Lung Cancer Gene Mutations Among Chinese Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 1251	5.3	3

210	ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. 2020 , 40, 4937-4946		4
209	The Significance of the Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 1214	5.3	5
208	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. 2020 , 10, 725		1
207	Mining potentially actionable kinase gene fusions in cancer cell lines with the KuNG FU database. 2020 , 7, 420		0
206	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020 , 12,	6.6	27
205	NRF2-Driven Transcription in Human Lung Cancer. <i>Molecular Cancer Research</i> , 2020 , 18, 1465-1476	6.6	3
204	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. 2020 , 9,		9
203	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. 2020 , 7, 50		5
202	Dysregulation of cancer genes by recurrent intergenic fusions. 2020 , 21, 166		8
201	High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy. 2020 , 8, 685		2
200	Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2393-2403	12.9	12
199	Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression. 2020 , 13, 7		38
198	Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program. 2020 , 16, 1031-1041		5
197	Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. 2020 , 23, 894-901		2
196	Real-time quantification of fusion transcripts with ligase chain reaction by direct ligation of adjacent DNA probes at fusion junction. <i>Analyst, The</i> , 2020 , 145, 3977-3982	5	1
195	Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer. 2020 , 117, 9912-9921		7
194	Integrative Analysis of NSCLC Identifies LINC01234 as an Oncogenic lncRNA that Interacts with HNRNPA2B1 and Regulates miR-106b Biogenesis. 2020 , 28, 1479-1493		40
193	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. 2021 , 16, 452-463		17

192	Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302. 2021 , 26, 515-522		2
191	Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, 49-57	4.9	12
190	Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform. 2020 , 10, LMT42		
189	Neuregulin Signaling in the Tumor Microenvironment. 2021 , 1270, 1-29		
188	Application of long-read sequencing to the detection of structural variants in human cancer genomes. 2021 , 19, 4207-4216		3
187	Dependency of LKB1-inactivated lung cancer on aberrant CRTC-CREB activation.		
186	Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. <i>Frontiers in Oncology</i> , 2020 , 10, 544579	5.3	0
185	Natural Compounds Targeting Major Signaling Pathways in Lung Cancer. 2021 , 821-846		3
184	Immunotherapy for -Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches. <i>Cancers</i> , 2021 , 13,	6.6	5
183	Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. 2021 , 11, 6685		4
182	Lorlatinib-induced visual and auditory hallucinations: A case report. 2021 , 9,		0
181	EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report. 2021 , 14, 2823-2828		0
180	The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. 2021 , 6,		13
179	Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review. 2021 , 9, 621		11
178	Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib. 2021 , e1414		1
177	The application of artificial intelligence in lung cancer: a narrative review.. 2021 , 10, 2478-2487		0
176	ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. 2021 , 17, 1709-1719		4
175	Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis. 2021 , 7, 33		10

174	Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation. 2021 , 10,		0
173	Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. 2021 , 1-10		4
172	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. 2021 , 10, 2890-2916		6
171	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer. 2021 , 28, 377-389		2
170	EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation. 2021 , 21, 190		0
169	Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. 2021 , 1, 123-123		0
168	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 157, 9-16	5.9	2
167	Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Implications from a Prospective Cohort Study. 2021 , 25, 3149-3159		2
166	ALK-positive non-small cell lung cancer; potential combination drug treatments. 2021 ,		0
165	An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1815-1824	4	0
164	One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer. 2021 , 26, e1683-e1692		1
163	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). 2021 , 17, 4237-4247		3
162	Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non-Small-Cell Lung Cancer from Chile, Brazil, and Peru. 2021 , 23, 1127-1137		
161	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. 2021 , 7, 1617-1625		20
160	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021 , 159, 66-73	5.9	2
159	A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients. 2021 , 12, 2773-2779		1
158	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. 2021 , 16, 2091-2108		19
157	Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma. 2021 , 12, 3011-3018		1

156	Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer). 2010 , 205-220	1
155	Adenocarcinoma. 2012 , 119-162	1
154	Resistance to ALK Inhibitors. 2016 , 147-163	1
153	Genomic Applications in Pulmonary Malignancies. 2019 , 363-392	1
152	Genomic Pathology of Lung Cancer. 2013 , 1-46	1
151	NonSmall Cell Lung Cancer. 2012 , 805-838	3
150	Cancer of the Lung. 2014 , 1143-1192.e13	3
149	ETS rearrangements in prostate cancer. 2012 , 14, 393-9	17
148	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs.	1
147	The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. 2020 , 2020, 3578748	3
146	Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. 2013 ,	10
145	Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. 2013 , 8, e64821	48
144	Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. 2014 , 9, e100866	34
143	Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. 2014 , 9, e110617	24
142	Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. 2015 , 10, e0117333	37
141	The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. 2015 , 10, e0124354	15
140	Chamber Specific Gene Expression Landscape of the Zebrafish Heart. 2016 , 11, e0147823	13
139	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. 2020 , 25, e130-e137	12

138	[Omics technologies in diagnostics of lung adenocarcinoma]. 2017 , 63, 181-210		2
137	Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. <i>Oncotarget</i> , 2016 , 7, 50575-50581	3-3	9
136	Concomitant rearrangement and mutation in non-small cell lung cancer patients: a literature review of 100 cases. <i>Oncotarget</i> , 2017 , 8, 59889-59900	3-3	26
135	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. <i>Oncotarget</i> , 2014 , 5, 4920-8	3-3	40
134	Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480. <i>Oncotarget</i> , 2017 , 8, 109319-109331	3-3	4
133	Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features. <i>Oncotarget</i> , 2014 , 5, 9295-307	3-3	9
132	Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. <i>Oncotarget</i> , 2018 , 9, 35181-35194	3-3	18
131	Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. <i>Oncotarget</i> , 2016 , 7, 23874-84	3-3	48
130	Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. <i>Oncotarget</i> , 2016 , 7, 33316-30	3-3	25
129	Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 37160-37176	3-3	5
128	Treating ALK-positive non-small cell lung cancer. 2018 , 6, 141		16
127	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. 2019 , 19, 595-630		17
126	A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer. 2019 , 19, 1129-1144		11
125	EML4-ALK in non-small-cell lung cancer: the breathtaking progress from benchtop to Phase III clinical trial. 2011 , 8, 55-61		1
124	ALK and NSCLC: Targeted therapy with ALK inhibitors. 2011 , 3, 21		16
123	[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy ?in Non-small Cell Lung Cancer Patients in Shandong]. 2017 , 20, 14-20		4
122	[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer]. 2018 , 21, 686-691		1
121	[Efficacy and Safety of Crizotinib in Advanced or Recurrent ?ALK-positive Non-small Cell Lung Cancer]. 2019 , 22, 488-493		1

120	Molecular biology of lung cancer. 2013 , 5 Suppl 5, S479-90	120
119	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. 2013 , 5 Suppl 5, S579-92	29
118	Research status and funding trends of lung cancer biomarkers. 2013 , 5, 698-705	10
117	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). 2013 , 2, 128-41	11
116	Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. 2015 , 4, 126-41	48
115	Crizotinib: A comprehensive review. 2013 , 2, 91-7	80
114	Determining factors of endobronchial ultrasound-guided transbronchial needle aspiration specimens for lung cancer subtyping and molecular testing. 2019 , 8, 404-411	9
113	A comparative analysis of immunohistochemistry and fluorescent hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: A search for a testing algorithm. 2017 , 54, 148-154	4
112	Design and Synthesis of an Anticancer Diarylurea Derivative with Multiple-Kinase Inhibitory Effect. 2012 , 33, 1571-1576	12
111	Global Epidemiology of Lung Cancer. 2019 , 85,	391
110	Non-small cell lung cancer--genetic predictors. 2013 , 157, 125-36	30
109	Molecular diagnostics of lung carcinomas. 2011 , 135, 622-9	21
108	Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. 2011 , 135, 655-64	27
107	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. 2013 , 2, 265-282	41
106	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer. 2014 , 10, 658-63	2
105	Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies. 2014 , 15, 3057-63	22
104	Clinical efficacy and possible applications of genomics in lung cancer. 2015 , 16, 1693-8	1
103	Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. 2016 , 8, e513	14

- 102 Role of Artificial Intelligence in Cancer Nanotheranostics. **2021**, 285-304
- 101 Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. **2021**, 21, 1107 1
- 100 Abstract PL2-1: The impact of genomic changes on the treatment of lung cancer. **2010**,
- 99 Lung Adenocarcinoma. **2011**, 177-183
- 98 Targeted Therapies for Non-small-Cell Lung Cancer. **2012**, 93-114
- 97 NonSmall Cell Lung Cancer. **2013**, 45-62
- 96 Discordant tumor response in the treatment of ALK-rearranged non-small cell lung cancer leads to the diagnosis of synchronous multiple primary lung cancer. **2013**, 02, 16-19
- 95 EML4-ALK Fusion Gene and Therapy with ALK-Targeted Agents in Non-Small Cell Lung Cancer. **2013**, 449-472
- 94 Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. **2014**, 75-118
- 93 The Role of Phase III Trials in Modern Drug Development. **2014**, 763-783
- 92 Case of an 18-year-old Female with EML4-ALK-positive Lung Adenocarcinoma. **2014**, 54, 153-157 3
- 91 Genomic Applications in Pulmonary Malignancies. **2015**, 383-413
- 90 Chromosomal Translocations in Lung Cancer. **2015**, 403-416
- 89 Lung Cancer: Diagnosis and Treatment Approach. **2015**, 97-144 2
- 88 Lung Cancer Among Asian Americans. **2016**, 107-136
- 87 Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. **2016**, 27-107
- 86 Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. **2016**, 7, 514-524 1
- 85 Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience. **2017**, 54, 197-202 2

84	Minor-Driver Mutant. 2017 , 199-212		
83	Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib. 2018 , 35, 527-529		
82	Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.		
81	Immunohistochemistry and Molecular Biology in Transbronchial Cryobiopsies. 2019 , 81-99		1
80	Anaplastic Lymphoma Kinase. 2019 , 31-54		
79	Clinic-pathologic features and gene fusion pattern of ALK and ROS1 in non-small cell lung cancer show association with household coal combustion.. 2019 , 8, 2164-2174		0
78	Lung Carcinoma. 2020 , 83-101		
77	In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. 2020 , 111, 1887-1898		2
76	Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.		1
75	Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. 2020 , 9, 2599-2617		0
74	Tyrosine phosphorylation is critical for ACLY activity in lipid metabolism and cancer.		
73	Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. <i>Lung Cancer</i> , 2021 , 162, 86-89	5.9	0
72	Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer. 2014 , 3, 379-81		5
71	[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation]. 2011 , 14, 880-4		2
70	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. 2011 , 36, 263-79		14
69	ALK-immunoreactive neoplasms. 2012 , 5, 397-410		29
68	Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. 2015 , 4, 149-55		17
67	[Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients]. 2017 , 20, 124-129		1

66	[Analysis of EML4-ALK gene fusion mutation in patients with non-small cell lung cancer]. 2015 , 18, 80-4		2
65	[A new target in non-small cell lung cancer: EML4-ALK fusion gene]. 2011 , 14, 538-42		1
64	[Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer]. 2018 , 21, 408-412		1
63	[EML4-ALK fusion gene in lung cancer and its biological function]. 2012 , 15, 112-6		2
62	[The EML4-ALK fusion gene in NSCLC and the clinical progress]. 2011 , 14, 435-40		
61	[Clinical meaning of EML4-ALK fusion gene in non-small cell lung cancer]. 2013 , 16, 97-101		1
60	[Mechanisms of resistance to EML4-ALK inhibitors in non-small cell lung cancer]. 2013 , 16, 48-53		
59	Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer. 2017 , 8, 729-735		2
58	Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. <i>Lung Cancer</i> , 2021 , 163, 7-13	5.9	0
57	Deepening the Knowledge of Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
56	Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data. <i>Oncotarget</i> , 2021 , 12, 2308-2315	3.3	0
55	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than .. <i>Frontiers in Oncology</i> , 2021 , 11, 750657	5.3	4
54	Epidemiological, clinical profile, and treatment outcome of stage iv nonsquamous nonsmall cell lung cancer patients presenting to tertiary care hospital in North India. <i>Oncology Journal of India</i> , 2021 , 5, 104	0.2	
53	The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor.. <i>Translational Oncology</i> , 2022 , 17, 101338	4.9	4
52	The Extent of Expression of Thyroid Transcription Factor 1, Cytokeratin 7, and Anaplastic Lymphoma Kinase in Lung Adenocarcinoma.. <i>Journal of Microscopy and Ultrastructure</i> , 2022 , 10, 10-14	0.9	
51	ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing.. <i>Clinical Chemistry</i> , 2022 ,	5.5	
50	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. <i>Npj Precision Oncology</i> , 2022 , 6, 5	9.8	0
49	Fusion-Associated Carcinomas of the Breast: Diagnostic, Prognostic, and Therapeutic Significance.. <i>Genes Chromosomes and Cancer</i> , 2022 ,	5	0

48	Analysis of the Efficacy of Afatinib in the Treatment of ALK-Positive Squamous Cell Carcinoma. <i>Asian Case Reports in Oncology</i> , 2022 , 11, 1-5	0	
47	Precision Medicine in Lung Cancer Theranostics: Paving the Way from Traditional Technology to Advance Era. <i>Cancer Control</i> , 2022 , 29, 107327482210773	2.2	
46	Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	2
45	MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumorigenesis.. <i>Cancers</i> , 2022 , 14,	6.6	0
44	Organoids in Lung Cancer Management.. <i>Frontiers in Surgery</i> , 2021 , 8, 753801	2.3	0
43	Sensitive detection of fusion transcripts with padlock probe-based continuous cascade amplification (P-CCA).. <i>Analyst, The</i> , 2022 ,	5	
42	Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.. <i>Cancer Medicine</i> , 2022 ,	4.8	0
41	Data_Sheet_1.PDF. 2019 ,		
40	Data_Sheet_1.xlsx. 2020 ,		
39	Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors.. <i>Clinical and Translational Oncology</i> , 2022 ,	3.6	0
38	Breast Cancer and Next-Generation Sequencing: Towards Clinical Relevance and Future. 2022 , 477-518		
37	EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity. <i>Molecular Cancer Research</i> , 2022 , 20, 854-866	6.6	1
36	Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. <i>Current Medical Research and Opinion</i> , 1-24	2.5	0
35	Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles. <i>Clinical Lung Cancer</i> , 2022 ,	4.9	
34	A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). <i>Expert Opinion on Pharmacotherapy</i> , 1-11	4	
33	Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian Versus Non-Asian Patients With Locally Advanced or Metastatic ALK Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. <i>Clinical Lung Cancer</i> , 2022 ,	4.9	0
32	Long-term Efficacy and Safety of Brigatinib in Crizotinib-Refractory +Non-Small Cell Lung Cancer: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. 2022 , 100385		0
31	TIMP3::ALK fusions characterize a distinctive myxoid fibroblastic tumor of the vocal cords: a report of 7 cases.		

- 30 Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study. 1-6 ○
- 29 Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer. ○
- 28 Profiling of gene fusion involving targetable genes in Chinese gastric cancer. **2022**, 14, 1528-1539 ○
- 27 Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study. **2022**, 238, 154105 ○
- 26 Understanding the Molecular Kinetics in NSCLC Through Computational Method. **2022**, 129-163 ○
- 25 Patient-by-Patient Deep Transfer Learning for Drug-Response Profiling Using Confocal Fluorescence Microscopy of Pediatric Patient-Derived Tumor-Cell Spheroids. **2022**, 1-1 ○
- 24 Brigatinib in Japanese patients with tyrosine kinase inhibitor-naïve ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study. ○
- 23 Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. 13, ○
- 22 Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors. 107815522211261 ○
- 21 Potential therapeutic strategy for EGFR mutant lung cancer with concomitant EML4-ALK rearrangement: combination of EGFR-TKIs and ALK inhibitors. **2022**, 100405 ○
- 20 Non-small cell lung cancer in China. 3
- 19 Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfanyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold. **2022**, 106188 1
- 18 Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-rearranged Lung Cancer. ○
- 17 Lorlatinib: new therapeutic options for ALK-positive patients. ○
- 16 Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. 9, 92-104 ○
- 15 Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. **2022**, 19, 14324 ○
- 14 The LCNetWork: An electronic representation of the mRNA-lncRNA-miRNA regulatory network underlying mechanisms of non-small cell lung cancer in humans, and its explorative analysis. **2022**, 101, 107781 ○
- 13 Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. **2022**, 14, 6101 ○

- 12 Current status and challenges of immunotherapy in ALK rearranged NSCLC. 12, ○
- 11 Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer. ○
- 10 Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. **2022**, ○
- 9 Real-World Treatment and Outcomes of ALK-Positive Metastatic NonSmall Cell Lung Cancer in a Southeast Asian Country. Volume 15, 31-41 ○
- 8 Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. **2023**, 7, ○
- 7 A detailed multi-omics analysis of GNB2 gene in human cancers. 84, ○
- 6 MicroRNA in lung cancer— novel potential way for early diagnosis and therapy. ○
- 5 Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). **2023**, 21, ○
- 4 Association of lung cancer with ALK and EGFR and its targeted therapy. 36, 560-566 ○
- 3 DNAFusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies. **2023**, 24, ○
- 2 Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers. **2023**, 23, ○
- 1 Brigatinib pharmacokinetics in patients with chronic hepatic impairment. ○